PT3326645T - Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam - Google Patents

Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam

Info

Publication number
PT3326645T
PT3326645T PT171928609T PT17192860T PT3326645T PT 3326645 T PT3326645 T PT 3326645T PT 171928609 T PT171928609 T PT 171928609T PT 17192860 T PT17192860 T PT 17192860T PT 3326645 T PT3326645 T PT 3326645T
Authority
PT
Portugal
Prior art keywords
differences
svcam
alpha
methods
correlating
Prior art date
Application number
PT171928609T
Other languages
English (en)
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PT3326645T publication Critical patent/PT3326645T/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT171928609T 2010-10-25 2011-10-24 Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam PT3326645T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40635810P 2010-10-25 2010-10-25
US40636510P 2010-10-25 2010-10-25

Publications (1)

Publication Number Publication Date
PT3326645T true PT3326645T (pt) 2020-06-23

Family

ID=46024768

Family Applications (1)

Application Number Title Priority Date Filing Date
PT171928609T PT3326645T (pt) 2010-10-25 2011-10-24 Métodos para determinar as diferenças na atividade da integrina alfa-4 através da correlação de diferenças nos níveis de svcam e/ou smadcam

Country Status (17)

Country Link
US (3) US20130337470A1 (pt)
EP (3) EP2632492B1 (pt)
JP (2) JP5847188B2 (pt)
AU (4) AU2011323820A1 (pt)
CA (1) CA2816016A1 (pt)
CY (1) CY1123060T1 (pt)
DK (1) DK3326645T3 (pt)
ES (2) ES2800066T3 (pt)
HK (1) HK1256157A1 (pt)
HR (1) HRP20200920T1 (pt)
HU (1) HUE050713T2 (pt)
LT (1) LT3326645T (pt)
PL (1) PL3326645T3 (pt)
PT (1) PT3326645T (pt)
RS (1) RS60565B1 (pt)
SI (1) SI3326645T1 (pt)
WO (1) WO2012061074A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061074A1 (en) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
MX2017006959A (es) * 2014-12-02 2017-08-10 Nestec Sa Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable.

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5338689A (en) 1987-08-24 1994-08-16 Stiftung Fur Diagnostische Forschung Method and card for detecting antigens and/or antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
NZ262615A (en) 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
BE1008817A6 (fr) 1994-10-28 1996-08-06 Univ Bruxelles Procede d'obtention d'adn bicatenaire membranaire humain, produit obtenu par ce procede et trousse de diagnostic le contenant.
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
US5965356A (en) 1997-01-31 1999-10-12 University Of Maryland, Baltimore Herpes simplex virus type specific seroassay
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999058573A1 (en) * 1998-05-13 1999-11-18 Genentech, Inc. Diagnosis and treatment of hepatic disorders
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
JP5113314B2 (ja) * 2000-09-01 2013-01-09 ザ センター フォー ブラッド リサーチ インク 所望のコンホメーションで安定させた改変ポリペプチド及び該ポリペプチドの作製方法
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PT1485127E (pt) 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
UY28170A1 (es) 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
EP3777880A1 (en) 2003-02-10 2021-02-17 Biogen MA Inc. Immunoglobulin formulation and method of preparation thereof
CA2555365A1 (en) 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
WO2005097162A2 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
EP1871806A2 (en) 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
LT2645106T (lt) * 2005-04-04 2017-09-11 Biogen Ma Inc. Imuninio atsako į terapinį agentą įvertinimo būdai
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
SG170058A1 (en) 2006-03-03 2011-04-29 Elan Pharm Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2708262A1 (en) 2007-12-07 2009-06-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors
US20100255508A1 (en) * 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2009141786A2 (en) 2008-05-21 2009-11-26 Piramal Life Sciences Limited Anti-inflammatory compounds
WO2010053316A2 (en) 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
WO2011137418A1 (en) * 2010-04-30 2011-11-03 Elan Pharmaceuticals, Inc. Selective integrin inhibitors
WO2012061074A1 (en) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS

Also Published As

Publication number Publication date
LT3326645T (lt) 2020-08-10
EP2632492A1 (en) 2013-09-04
JP2015215363A (ja) 2015-12-03
EP3326645B1 (en) 2020-03-18
HK1256157A1 (zh) 2019-09-13
AU2017201658A1 (en) 2017-03-30
AU2017201658B2 (en) 2019-03-21
WO2012061074A1 (en) 2012-05-10
EP2632492B1 (en) 2017-10-04
CY1123060T1 (el) 2021-10-29
US20220206012A1 (en) 2022-06-30
PL3326645T3 (pl) 2020-09-21
AU2019204089A1 (en) 2019-07-04
AU2011323820A1 (en) 2013-05-23
US20160291035A1 (en) 2016-10-06
EP3326645A1 (en) 2018-05-30
EP3722808A1 (en) 2020-10-14
JP5847188B2 (ja) 2016-01-20
EP2632492A4 (en) 2014-04-02
RS60565B1 (sr) 2020-08-31
SI3326645T1 (sl) 2020-09-30
HRP20200920T1 (hr) 2020-10-30
ES2800066T3 (es) 2020-12-23
AU2021212059A1 (en) 2021-08-26
HUE050713T2 (hu) 2020-12-28
ES2654820T3 (es) 2018-02-15
US20130337470A1 (en) 2013-12-19
CA2816016A1 (en) 2012-05-10
DK3326645T3 (da) 2020-06-15
JP2014500950A (ja) 2014-01-16
US11079393B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
EP2700061A4 (en) SYSTEMS AND METHOD FOR ANALYZING ENERGY CONSUMPTION
HK1206065A1 (en) Compositions and methods for analyte detection
HK1193471A1 (zh) 識別和測量網狀細胞
GB2516204B (en) Multi-cue object detection and analysis
EP2673631A4 (en) METHOD AND SYSTEMS FOR DETERMINING THE PRESENCE OR QUANTITY OF TESTOSTERONE IN A SAMPLE
SG11201401913YA (en) Systems and methods for biological analysis
EP2456361A4 (en) SYSTEMS FOR CONTINUOUS ANALYTING MEASUREMENT AND SYSTEMS AND METHOD FOR THE IMPLEMENTATION THEREOF
EP2683810A4 (en) METHOD AND SYSTEM FOR CELL DETECTION AND ANALYSIS
SG11201401016YA (en) Web inspection calibration system and related methods
EP2663864A4 (en) IMMUNODIVERSITY QUICK PROCEDURE AND ITS APPLICATION
SG11201401956XA (en) Undifferentiated cell detection method and complex carbohydrate detection method
EP2553657A4 (en) METHODS AND APPARATUS FOR FACIAL DETECTION
EP2703494A4 (en) CELL ANALYSIS METHOD, DEVICE AND PROGRAM
EP2584964A4 (en) SYSTEMS AND METHODS FOR MONITORING SUBSTANCE TO BE ANALYZED
EP2705135A4 (en) SYSTEMS AND METHODS FOR ANALYZING BASOPHILES
ZA201208522B (en) Methods for measuring enzyme activity useful in determining cell viability in non-purified sapmles
IL222752A0 (en) Acoustic methods and systems for detecting terahertz radioation
EP2533049A4 (en) PRETREATMENT SOLUTION FOR IMMUNOHISTOCHEMICAL COLORING AND CONDENSED SOLUTION THEREOF
EP2788794A4 (en) PERMEABILITY PREDICTION SYSTEMS AND METHODS INVOLVING QUADRATIC DISCRIMINANT ANALYSIS
EP2612256A4 (en) IMPLEMENTATION OF »WHAT-IF-ANALYSIS
EP2726813A4 (en) SURFACE MEASURING SYSTEM AND METHOD
EP2650875A4 (en) PITCH ORDER DETERMINATION DEVICE, TRACK ORDER DETERMINATION METHOD, AND TRACK ORDER DETERMINATION PROGRAM
EP2640407A4 (en) PROCESS FOR INCREASING THE EXPRESSION AND ACTIVITY OF NEPRILYSIN
EP2576809A4 (en) MEASURE A YEAST CONCENTRATION AND LIFE CAPABILITY
EP2553115A4 (en) METHODS OF CULTURE AND ANALYSIS OF CELLS